Key Stats for HCA Healthcare Stock
- Price change for HCA Healthcare stock: -9%
- $HCA Share Price as of Apr. 24: $432
- 52-Week High: $557
- $HCA Stock Price Target: $543
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
HCA Healthcare (HCA) stock dropped more than 8% on Friday after the company reported a quarter that was hurt by an unusually mild flu season and rising concerns about insured patient volumes.
The numbers tell the story.
- Respiratory-related admissions fell 42% year-over-year.
- ER visits tied to respiratory illness dropped 32%.
- Those aren’t rounding errors — they’re significant volume drivers that simply weren’t there this quarter.
- Management estimated the weather and flu headwinds cost the company roughly $180 million in adjusted EBITDA.
- Adjusted EPS came in at $7.15, narrowly beating the $7.13 estimate.
- Revenue grew 4.3% to $19.1 billion and came in slightly above consensus.
- Adjusted EBITDA of $3.8 billion rose 1.8% but missed the $3.9 billion expectation.
- Exchange-covered admissions fell roughly 15% year-over-year.
- Uninsured admissions rose about 16%.
- That shift is exactly what management warned about when they guided to a $600–$900 million EBITDA headwind from exchange-related disruption for the full year.
The flu miss was bad enough on its own. But HCA Healthcare stock also faced selling pressure from a bigger worry — the unwind of Affordable Care Act subsidies.
The good news is that HCA reaffirmed its full-year guidance.
- Revenue is still expected to come in between $76.5 billion and $80 billion.
- Full-year EPS guidance remains $29.10–$31.50.
- Management said February and March volumes rebounded after a rough January, and they expect 2–3% volume growth over the remaining three quarters.
There was also a partial offset. Medicaid supplemental payment benefits came in $120 million above expectations, driven by new program approvals in Georgia and Texas.
That helped cushion the blow but wasn’t enough to fully reassure investors.
See analysts’ growth forecasts and price targets for HCA Healthcare stock (It’s free) >>>
What the Market Is Telling Us About HCA Healthcare Stock
HCA Healthcare stock is already down about 8% year-to-date heading into today.
The stock sits more than 22% below its 52-week high. Investors are pricing in a lot of uncertainty — around ACA enrollment, uncompensated care costs, and whether volume trends can recover.
Management’s message was clear: the flu headwind was temporary, the core business is intact, and the setup for the rest of the year remains on track.
That may prove true.
But HCA Healthcare stock needs to show it in the numbers over the next few quarters before sentiment shifts.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does HCA Healthcare Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
